NAVA - Navamedic acquires Novicus Pharma


13/02-2019 17:00:04: (NAVA) Navamedic acquires Novicus Pharma

Reference is made to the stock exchange announcement made by Navamedic ASA (the
"Company" or "Navamedic") on 21 December 2018 concerning the process of a
potential acquisition of Novicus Pharma AS ("Novicus Pharma" or "Novicus").

Navamedic has today entered into a Share Purchase Agreement to acquire 100% of
the shares in Novicus Pharma. The acquisition will strengthen Navamedic's
executive team, product pipeline and network in the pharma industry.

As part of the proposed transaction, the three founders of Novicus Pharma have
agreed to become key members of the Navamedic management team incl Kathrine
Gamborg Andreassen as CEO of Navamedic, Ole Henrik Eriksen as COO and Astrid T
Bratvedt as Vice President of R&D.

Navamedic has a strong marketing and distribution platform to hospitals and
pharmacies in the Nordic and Baltic region as well as an innovative Medtech
division.
"The two companies complement each other very well. Together they will be a
unique platform for further growth", says Kathrine Gamborg Andreassen

"Navamedic has a solid foothold in pharmacy and health care industry in the
Nordic region, while Novicus Pharma has in a short time established a pipeline
of unique products targeting specific consumer needs in the same region. We
believe that current trends in the population, specifically related to lifestyle
diseases and other common ailments, represents significant growth opportunities
for the combined company" Andreassen explains.

Terje Bakken, Chairman of Navamedic concludes;

"Our ambition is to complement the strong platform of Navamedic with the new
opportunities from Novicus Pharma to create a new Nordic pharmaceutical entity
with multiple growth opportunities. We see great opportunities within the
current Pharma & Healthcare division and we're very pleased to have Novicus
onboard to enhance and execute the growth plan going forward. The transaction is
done on fully aligned incentives with all parties encouraged for a positive
journey going forward"

Transaction details

Novicus will be acquired from companies owned by the founders of Novicus as
named above. The agreed consideration for 100% of the shares in Novicus is 11.67
MNOK, which will be settled on closing of the transaction by issuance of
1,000,000 new shares in Navamedic to the sellers (the "Consideration Shares").
The Consideration Shares will be issued by the Company's board of directors
pursuant to a board authorization granted by the Company's 2018 annual general
meeting to increase the share capital in the Company in connection with, inter
alia, strategic acquisitions with settlement in new shares in Navamedic. The
Consideration Shares will be subject to a lock up period of 24 months from
closing, under which the sellers of Novicus cannot sell, pledge or otherwise
transfer the Consideration Shares.

The transaction is expected to close during the course of next week.

For further information:

Toril Ås, CFO, Navamedic
Email: toril.as@navamedic.com
Telephone: +47 957 01 071

Redigert 19.01.2021 kl 04:08 Du må logge inn for å svare
inva
13.02.2019 kl 17:13 1362

"The agreed consideration for 100% of the shares in Novicus is 11.67
MNOK"

Over 11 millioner for Novicus Pharma? Her må gevinsten være stor for Navamedic sine eksisterende aksjonærer??
Det er uansett rart at de ikke tallfester dette i meldingen. Men IRIC/Bakken ville vel ikke gått så høyt hvis det ikke var verdt det.
Computum
13.02.2019 kl 20:05 1303

Det var endel mer enn jeg hadde tenkt meg for et nystartet firma. Da må enten kontraktene eller personellet være verdifulle. Det kan ihvertfall ikke være kopimaskina og gardinene som er så mye verdt.
Blir spennende å få høre mer imorgen.
inva
13.02.2019 kl 20:25 1277

Jeg hadde sett for meg ca halvparten. Når det er sagt har jeg veldig tro på dette. Det ble presentert noen drypp på EGF om status i NP og det virket veldig lovende. Det Navamedic betaler for er nok kun en "overgangssum" for de 2(3) ansatte og de potensielle avtalene de jobber med og som de eventuelt allerede har inngått.
navas
13.02.2019 kl 21:02 1246

Også positivt at aksjene som utstedes som betaling til eierne av Novicus Pharma låses fra markedstilgang i en periode på to år,
Blir spennende i morgen. Har ikke store forventninger til resultatet, men guidingen framover må det nå være lov å ha betydelige forventninger til.
inva
27.02.2019 kl 19:30 1055

Navamedic har avsluttet oppkjøpet av Novicus i dag:


27/02-2019 15:15:16: (NAVA) Navamedic has completed the acquisition of Novicus Pharma

Reference is made to the stock exchange announcement from Navamedic ASA (the
«Company») on 13 February 2019 regarding the Company's acquisition of Novicus
Pharma AS. The Company has today completed the acquisition of Novicus Pharma AS.

In connection with the acquisition, the board of directors in the Company has
resolved to issue 1,000,000 new shares in the Company at a price of NOK 11.67
per new share. The new shares are issued as consideration to the sellers of
Novicus Pharma AS pursuant to an authorization granted by the Company's annual
general meeting on 7 June 2018. Following registration of the share capital
increase with the Norwegian Register of Business Enterprises, the Company's new
share capital will be NOK 11,867,673, divided on 11,867,673 shares, each with a
nominal value of NOK 1.

For further information, please contact:

Toril Ås

Chief Financial Officer (CFO)

Redigert 27.02.2019 kl 19:30 Du må logge inn for å svare
skuggen
05.03.2019 kl 17:28 925

Ekstraordinær generalforsamling i Nopa, 8.3.19.
Redigert 05.03.2019 kl 17:30 Du må logge inn for å svare